Fig. 1
Nuclear MIRLET7D targets can be used as novel IPF markers. a RNA-sequencing in lung homogenates from Ctrl and IPF patients31. Volcano plot representing the significance (−log10 P-values after Welch’s t-test) vs. expression fold change (log2 expression ratios) between average of Ctrl and two IPF patients. Magenta dots show transcripts with positive log2 expression ratios. Black dots show MIRLET7D targets. Green dots show fibrotic markers. b Top: KEGG-based enrichment analysis of transcripts upregulated in both IPF patients (magenta dots in a) using DAVID bioinformatics tool and plotted by highest significance (−log10 of modified Fisher’s exact P-value). Color of the bar represents number of genes in each group based on the legend. ECM, extracellular matrix. Bottom: correlation analysis between MIRLET7D targets and fibrotic by linear regression of log2 FC value of a single MIRLET7D target paired with a single fibrotic marker from the two selected patients. All values were patient-matched and correlation clustering (data mining) from negative to positive values. c Mature MIRLET7D-specific TaqMan assay and qRT-PCR analysis of the indicated coding RNAs (cRNA) using total lung homogenates from Ctrl (n = 5 biologically independent samples) and IPF patients (n = 10 biologically independent samples). Data are shown as means ± SEM. Asterisks in all plots, P-values after unpaired t-test, one-tailed, ***P < 0.001; **P < 0.01; *P < 0.05. Source data are provided as a Source Data file
